AstraZeneca’s Soliris approved in Japan for paediatric gMG patients
The drug is the first to be approved in Japan to treat children and adolescents with generalised myasthenia gravis
Read More
Tag: generalised myasthenia gravis
AstraZeneca’s Soliris given EU CHMP recommendation for marketing authorisation
The authorisation would include certain patients with refractory generalised myasthenia gravis
Read More
US expands use of Alexion rare disease therapy Soliris
Alexion’s rare disease therapy Soliris can now be used in the US to treat generalised myasthenia gravis in patients who are anti-acetylcholine receptor antibody-positive, offering this group the first new treatment option in more than 60 years.
Read More
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
